National MS Society: Results Announced - "BTK Inhibitor" Fenebrutinib Meets Primary Endpoint in Phase 3 Trials in People With Primary Progressive and Relapsing MS
November 11, 2025
November 11, 2025
NEW YORK, Nov. 11 -- The National Multiple Sclerosis Society issued the following news:
* * *
Results Announced: "BTK Inhibitor" Fenebrutinib Meets Primary Endpoint in Phase 3 Trials in People with Primary Progressive and Relapsing MS
Genentech, a member of the Roche Group, announced that fenebrutinib - an experimental, oral BTK-inhibitor - met the primary endpoint of slowing disability progression at least as effectively as ocrelizumab in the FEN . . .
* * *
Results Announced: "BTK Inhibitor" Fenebrutinib Meets Primary Endpoint in Phase 3 Trials in People with Primary Progressive and Relapsing MS
Genentech, a member of the Roche Group, announced that fenebrutinib - an experimental, oral BTK-inhibitor - met the primary endpoint of slowing disability progression at least as effectively as ocrelizumab in the FEN . . .